BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111-125. [PMID: 29956210 DOI: 10.1007/978-981-10-8684-7_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Katsiki N, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation? Metabolism 2018;87:A10-3. [DOI: 10.1016/j.metabol.2018.08.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
2 Celiberto LS, Pinto RA, Rossi EA, Vallance BA, Cavallini DCU. Isolation and Characterization of Potentially Probiotic Bacterial Strains from Mice: Proof of Concept for Personalized Probiotics. Nutrients 2018;10:E1684. [PMID: 30400640 DOI: 10.3390/nu10111684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Emerenziani S, Guarino MPL, Trillo Asensio LM, Altomare A, Ribolsi M, Balestrieri P, Cicala M. Role of Overweight and Obesity in Gastrointestinal Disease. Nutrients 2019;12:E111. [PMID: 31906216 DOI: 10.3390/nu12010111] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
4 Hou W, Li J, Cao Z, Lin S, Pan C, Pang Y, Liu J. Decorating Bacteria with a Therapeutic Nanocoating for Synergistically Enhanced Biotherapy. Small 2021;:e2101810. [PMID: 34365713 DOI: 10.1002/smll.202101810] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Müller H, Dagher G, Loibner M, Stumptner C, Kungl P, Zatloukal K. Biobanks for life sciences and personalized medicine: importance of standardization, biosafety, biosecurity, and data management. Current Opinion in Biotechnology 2020;65:45-51. [DOI: 10.1016/j.copbio.2019.12.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
7 Maung K, Ramalingam S, Chaudhry M, Ren Y, Jung SH, Romero K, Corbet K, Chao NJ, Choi T, Diehl AM, Diehl L, Gasparetto C, Horwitz M, Long GD, Lopez RD, Rizzieri DA, Sarantopoulos S, Sullivan KM, Bashir MR, Sung AD. Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS One 2020;15:e0238824. [PMID: 32915853 DOI: 10.1371/journal.pone.0238824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Geng J, Ni Q, Sun W, Li L, Feng X. The links between gut microbiota and obesity and obesity related diseases. Biomedicine & Pharmacotherapy 2022;147:112678. [DOI: 10.1016/j.biopha.2022.112678] [Reference Citation Analysis]
9 Liu X, Sun R, Li Z, Xiao R, Lv P, Sun X, Olson MA, Gong Y. Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. Arch Biochem Biophys 2021;711:109019. [PMID: 34478730 DOI: 10.1016/j.abb.2021.109019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cao Z, Wang X, Pang Y, Cheng S, Liu J. Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment. Nat Commun 2019;10:5783. [PMID: 31857577 DOI: 10.1038/s41467-019-13727-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
11 Francini-Pesenti F, Spinella P, Calò LA. Potential role of phytochemicals in metabolic syndrome prevention and therapy. Diabetes Metab Syndr Obes 2019;12:1987-2002. [PMID: 31632110 DOI: 10.2147/DMSO.S214550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer Cachexia: More Than Skeletal Muscle Wasting. Trends in Cancer 2018;4:849-60. [DOI: 10.1016/j.trecan.2018.10.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
13 Shen C, Pan Z, Wu S, Zheng M, Zhong C, Xin X, Lan S, Zhu Z, Liu M, Wu H, Huang Q, Zhang J, Liu Z, Si Y, Tu H, Deng Z, Yu Y, Liu H, Zhong Y, Guo J, Cai J, Xian S. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway. J Ethnopharmacol 2021;279:114340. [PMID: 34171397 DOI: 10.1016/j.jep.2021.114340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yang Q, Zhang L, Li Q, Gu M, Qu Q, Yang X, Yi Q, Gu K, Kuang L, Hao M, Xu J, Yang H. Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus. BMC Microbiol 2022;22. [DOI: 10.1186/s12866-022-02526-w] [Reference Citation Analysis]
15 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem 2019;120:2713-20. [PMID: 30443932 DOI: 10.1002/jcb.27635] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
17 Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health 2019;38:81-8. [PMID: 31384519 DOI: 10.12938/bmfh.18-032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
18 Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. Curr Obes Rep. 2019;8:317-332. [PMID: 31175629 DOI: 10.1007/s13679-019-00352-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 35.5] [Reference Citation Analysis]
19 Xu X, Wang H, Guo D, Man X, Liu J, Li J, Luo C, Zhang M, Zhen L, Liu X. Curcumin modulates gut microbiota and improves renal function in rats with uric acid nephropathy. Ren Fail 2021;43:1063-75. [PMID: 34187292 DOI: 10.1080/0886022X.2021.1944875] [Reference Citation Analysis]
20 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
21 Cao Z, Lin S, Liu J. Bacteria-Based Microdevices for the Oral Delivery of Macromolecules. Pharmaceutics 2021;13:1610. [PMID: 34683903 DOI: 10.3390/pharmaceutics13101610] [Reference Citation Analysis]
22 Ji Y, Elkin K, Yip J, Guan L, Han W, Ding Y. From circadian clocks to non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2019;13:1107-12. [DOI: 10.1080/17474124.2019.1684899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 He B, Jiang J, Shi Z, Wu L, Yan J, Chen Z, Luo M, Cui D, Xu S, Yan M, Zhang S, Chen Z. Pure total flavonoids from citrus attenuate non-alcoholic steatohepatitis via regulating the gut microbiota and bile acid metabolism in mice. Biomed Pharmacother 2021;135:111183. [PMID: 33401222 DOI: 10.1016/j.biopha.2020.111183] [Cited by in F6Publishing: 1] [Reference Citation Analysis]